Alpha 2.0
Login Register
» Authors » Teodora Kaltcheva

Teodora Kaltcheva

Explore the profile of Teodora Kaltcheva including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 26
Citations 370
Followers 0
Related Specialties
Hematology
Oncology
General Medicine
Top 10 Co-Authors
Don J Diamond
Corinna La Rosa
Qiao Zhou
Flavia Chiuppesi
Felix Wussow
Ryotaro Nakamura
Yoonsuh Park
Joy Martinez
Mindy Kha
Angelina Iniguez
Published In
J Virol
bioRxiv
Am J Hematol
Haematologica
Clin Cancer Res
Affiliations
Soon will be listed here.
Recent Articles
1.
Highly stable and immunogenic CMV T cell vaccine candidate developed using a synthetic MVA platform
Yll-Pico M, Park Y, Martinez J, Iniguez A, Kha M, Kim T, et al.
NPJ Vaccines . 2024 Mar; 9(1):68. PMID: 38555379
Human cytomegalovirus (CMV) is the most common infectious cause of complications post-transplantation, while a CMV vaccine for transplant recipients has yet to be licensed. Triplex, a multiantigen Modified Vaccinia Ankara...
2.
Cytomegalovirus Triplex vaccine in pediatric hematopoietic stem cell transplant patients at high risk for cytomegalovirus complications: evaluation of vaccine safety, immunogenicity and impact on viremia requiring antivirals
La Rosa C, Park Y, Yang D, Zhou Q, Kaltcheva T, Karras N, et al.
Haematologica . 2024 Mar; 109(7):2303-2308. PMID: 38426277
No abstract available.
3.
A phase II randomized, placebo-controlled, multicenter trial to evaluate the efficacy of cytomegalovirus PepVax vaccine in preventing cytomegalovirus reactivation and disease after allogeneic hematopoietic stem cell transplant
Nakamura R, La Rosa C, Yang D, Hill J, Rashidi A, Choe H, et al.
Haematologica . 2024 Feb; 109(6):1994-1999. PMID: 38328852
No abstract available.
4.
Stimulation of Potent Humoral and Cellular Immunity via Synthetic Dual-Antigen MVA-Based COVID-19 Vaccine COH04S1 in Cancer Patients Post Hematopoietic Cell Transplantation and Cellular Therapy
Chiuppesi F, Ortega-Francisco S, Gutierrez M, Li J, Ly M, Faircloth K, et al.
Vaccines (Basel) . 2023 Sep; 11(9). PMID: 37766168
Hematopoietic cell transplantation (HCT) and chimeric antigen receptor (CAR)-T cell patients are immunocompromised, remain at high risk following SARS-CoV-2 infection, and are less likely than immunocompetent individuals to respond to...
5.
Functional SARS-CoV-2-specific T cells of donor origin in allogeneic stem cell transplant recipients of a T-cell-replete infusion: A prospective observational study
La Rosa C, Chiuppesi F, Park Y, Zhou Q, Yang D, Gendzekhadze K, et al.
Front Immunol . 2023 Mar; 14:1114131. PMID: 36936918
Clinical Trial Registration: clinicaltrials.gov, identifier NCT04666025.
6.
Hematopoietic stem cell donor vaccination with cytomegalovirus triplex augments frequencies of functional and durable cytomegalovirus-specific T cells in the recipient: A novel strategy to limit antiviral prophylaxis
La Rosa C, Aldoss I, Park Y, Yang D, Zhou Q, Gendzekhadze K, et al.
Am J Hematol . 2023 Jan; 98(4):588-597. PMID: 36594185
To enhance protective cytomegalovirus (CMV)-specific T cells in immunosuppressed recipients of an allogeneic hematopoietic cell transplant (HCT), we evaluated post-HCT impact of vaccinating healthy HCT donors with Triplex. Triplex is...
7.
Adoptive transfer of functional SARS-COV-2-specific immunity from donor graft to hematopoietic stem cell transplant recipients
La Rosa C, Chiuppesi F, Park Y, Gendzekhadze K, Zhou Q, Faircloth K, et al.
Am J Hematol . 2022 Sep; 97(11):E404-E407. PMID: 36053823
No abstract available.
8.
Vaccine-induced spike- and nucleocapsid-specific cellular responses maintain potent cross-reactivity to SARS-CoV-2 Delta and Omicron variants
Chiuppesi F, Zaia J, Faircloth K, Johnson D, Ly M, Karpinski V, et al.
iScience . 2022 Jul; 25(8):104745. PMID: 35846380
Cell-mediated immunity may contribute to providing protection against SARS-CoV-2 and its variants of concern (VOC). We developed COH04S1, a synthetic multiantigen modified vaccinia Ankara (MVA)-based COVID-19 vaccine that stimulated potent...
9.
Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates
Chiuppesi F, Nguyen V, Park Y, Contreras H, Karpinski V, Faircloth K, et al.
NPJ Vaccines . 2022 Jan; 7(1):7. PMID: 35064109
Second-generation COVID-19 vaccines could contribute to establish protective immunity against SARS-CoV-2 and its emerging variants. We developed COH04S1, a synthetic multiantigen modified vaccinia Ankara-based SARS-CoV-2 vaccine that co-expresses spike and...
10.
Successful outcome of pre-engraftment COVID-19 in an HCT patient: impact of targeted therapies and cellular immunity
Pourhassan H, La Rosa C, Chiuppesi F, Puing A, Aldoss I, Park Y, et al.
Blood Adv . 2022 Jan; 6(6):1645-1650. PMID: 35008104
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has emerged as a global pandemic that upended existing protocols and practices, including those for allogeneic...